|DB00110||Palivizumab||For prophylaxis of respiratory diseases casued by respiratory syncytial virus.|
|DB06310||Motavizumab||Investigated for use/treatment in viral infection and pediatric indications.|
|DB08902||Raxibacumab||Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. |
|DB10062||Rabies virus inactivated antigen, B||Not Available|
|DB10283||Rabies virus inactivated antigen, A||Not Available|
|DB11604||Tetanus Immune Globulin||For use as prophylaxis against tetanus in patients who are injured and have incomplete of uncertain immunization statu [FDA Label]. May also be used in the treatment of active tetanus.|
|DB13886||Human cytomegalovirus immune globulin||It is used to prevent cytomegalovirus (CMV) disease after organ transplant [L2225].
Cytomegalovirus Immune Globulin Intravenous (Human) is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas, and heart [FDA label].
In transplants of these organs other than the kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IGIV should be considered in combination with ganciclovir [FDA label].|
|DB05336||Obiltoxaximab||Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.|
|DB13140||Bezlotoxumab||Prevents recurrence of Clostridium difficile infection in people 18 years or older who are either currently receiving treatment for C. difficile infection or have a high risk of recurrence. |